Pharma Financial Squeeze Bodes Ill for Genomics
‘Caution: Tougher Times Ahead’ may be an apt sign for biotech in general and genomics in particular, according to a panel of leading venture capitalists.
DeCode’s Genetic Breakthrough Barely Registers
DeCode Genetics published an important genetic map–assembled by methods very different from those used to create the sequence of the human genome–that will make it much easier for scientists to hunt down new genes linked to disease. But DeCode’s stock continues to languish.
Celera abandons gene sequencing
The company that shared the glory for unravelling the code of life of human beings has turned its back on gene sequencing. Celera Genomics of Rockville, Maryland, announced this week that it is to develop drugs instead
Where the Biotech Bets Are
John McCamant of The Medical Technology Stock Letter tells where he’s making his in this poorly performing sector.
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.
Recent Comments